Treatment for Hyperemesis Gravidarum is effective at Antai Hospital. Our HG vaccine works in just up to 4 injections and patients are usually fully treated in 4 days, and are allowed to go home. This HG Vaccine is Antai’s proprietary treatment for any form of Hyperemesis with a guaranteed success rate of 95%. The dosage however varies depending on the severity of your HG and the presence of pre-existing disorders.
Up to 80% of all pregnant women experience some form of nausea and vomiting during their pregnancy. The International Statistical Classification of Disease and Related Health Problems, Tenth Revision, defines hyperemesis gravidarum (HG) as persistent and excessive vomiting starting before the end of the 22nd week of gestation and further subdivides the condition into mild and severe, with severe being associated with metabolic disturbances such as carbohydrate depletion, dehydration, or electrolyte imbalance. HG is a diagnosis of exclusion, characterized by prolonged and severe nausea and vomiting, dehydration, large ketonuria, and more than 5% body weight loss. Affecting approximately 0.3%–2.0% of pregnancies, HG is the commonest indication for admission to hospital in the first half of pregnancy and is second only to preterm labor as a cause of hospitalization during pregnancy. According to the Hyperemesis Education and Research Foundation, conservative estimates indicate that HG can cost a minimum of $200 million annually in in-house hospitalizations in the United States. Taking into account other factors such as emergency department treatments, potential complications of severe HG, and the fact that up to 35% of women with paid employment will lose time from work through nausea, the actual cost of HG to the economy is significantly higher.
HG and adverse fetal pregnancy outcomes
HG has been reported to be associated with an increased risk for adverse pregnancy outcomes such as low birth weight, preterm birth, and small-for-gestational age infants. A recent systematic review identified no association with APGA scores, congenital anomalies, or perinatal death.25 Several additional studies were not included in the aforementioned review either because of inclusion criteria or because of publication after the review search period. McCarthy et al performed a prospective cohort study of 423 nulliparous women. HG was defined as repeated vomiting in early pregnancy not resulting from other causes (eg. gastroenteritis) and requiring any of the following: inpatient admission, day stay with intravenous fluids, nasogastric feeding (at home or in hospital), or vomiting associated with loss of more than 5% of her booking weight. Women with hospitalized HG were considered as having severe HG. Secondary outcomes included spontaneous preterm birth, pre-eclampsia, birthweight, small-for-gestational age infants, and infant sex ratio. Women with severe HG had an increased risk of having a spontaneous preterm birth compared with women without HG. No significant associations were observed among other secondary outcomes.
For the treatment, patients are urged to receive it before conceiving, and your condition can be completely eliminated during the pregnancy, ensuring you a smooth one. This treatment is fully contractual and comes with a full refund guaranteed if treatment outcomes are unsatisfactory. At Antai Hospital, we take every HG patient seriously regardless of your severity, and we will do our best to help you overcome it with Antai’s HG Vaccine.